Gold bars to be exempt from tariffs, White House clarifies
Fernando M. Rodrigues, President of BetterHelp, a division of Teladoc Health, Inc. (NYSE:TDOC), recently sold shares of the company in two separate transactions. The sale comes as Teladoc’s stock has declined 46.5% over the past year, though InvestingPro analysis shows the company maintains a GOOD financial health score. According to a recent SEC filing, Rodrigues sold a total of 4,166 shares across two days, amounting to approximately $33,965.
On March 20, Rodrigues sold 1,503 shares at an average price of $8.424 per share, totaling $12,661. The following day, he sold an additional 2,663 shares at a price of $8 per share, yielding $21,304. These transactions were conducted under a pre-established Rule 10b5-1 trading plan, which Rodrigues adopted and later amended in November 2024. The current share price sits between analysts’ targets of $8-14, with the company trading at a high EBITDA multiple of 55x.
The sales were part of a series of transactions involving restricted stock units that converted to common stock. Rodrigues initially acquired 4,166 shares on March 19 through the vesting of restricted stock units, which were granted to him in 2024. Following these transactions, Rodrigues no longer holds any shares directly. For comprehensive insider trading analysis and additional insights, access the detailed Teladoc Health Pro Research Report on InvestingPro.
In other recent news, Teladoc Health Inc. reported its fourth-quarter 2024 earnings, revealing a revenue of $640.5 million, which slightly surpassed the forecast of $638.5 million. However, the company’s earnings per share (EPS) came in at -0.28, missing the expected -0.23. For the full year 2024, Teladoc’s revenue was $2.6 billion, marking a 1% decrease from the previous year. In a strategic move, Teladoc has partnered with Gifthealth, Eli Lilly (NYSE:LLY)’s LillyDirect pharmacy partner, to enhance its Comprehensive Weight Care Program by integrating access to the medication Zepbound (tirzepatide).
Truist Securities maintained a Hold rating on Teladoc with a price target of $10.00, following this partnership. Meanwhile, Stifel also retained its Hold rating with a price target of $9.00, noting that Teladoc’s earnings and guidance were below market consensus but aligned with their projections. Analysts from Needham reiterated a Hold rating, citing mixed fourth-quarter results and challenges such as the loss of a large client and currency exchange headwinds. The company aims to stabilize its BetterHelp segment, which offers online counseling, with efforts towards international expansion and a new weekly payment model. These developments reflect Teladoc’s ongoing efforts to navigate current challenges while pursuing growth opportunities in the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.